A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy.

Lin, Amy M

A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. [electronic resource] - BJU international Oct 2006 - 763-9 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

1464-4096

10.1111/j.1464-410X.2006.06396.x doi


Aged
Aged, 80 and over
Antineoplastic Agents--adverse effects
Benzamides
Humans
Imatinib Mesylate
Male
Middle Aged
Neoplasm Recurrence, Local--blood
Piperazines--adverse effects
Prostate-Specific Antigen--blood
Prostatic Neoplasms--blood
Pyrimidines--adverse effects
Treatment Failure